On September 30, 2025, IceCure Medical Ltd. announced its participation at the European Society of Breast Imaging (EUSOBI) Congress 2025, held in Aberdeen, United Kingdom, from September 25-27, 2025. The company's exclusive workshop, titled 'Unlocking De-Escalation of Care: Cryoablation for Breast Cancer,' was filled to capacity, indicating significant interest from medical professionals in this evolving treatment paradigm.
During the congress, five abstracts from doctors utilizing ProSense® for breast cancer cryoablation in Europe were presented, showcasing growing clinical evidence and adoption. Dr. Francesca Pugliese was awarded a Young Physician-Scientist Grant for her study on post-procedure lesion conspicuity imaging, which was selected as one of the top five abstracts. These presentations highlight the increasing momentum for ProSense® adoption in the treatment of early-stage breast cancer in Europe.
IceCure's CEO, Eyal Shamir, stated that ProSense® represents the next step in the de-escalation of care for early-stage breast cancer, offering a minimally invasive, outpatient procedure with superior cosmetic outcomes and effectiveness comparable to surgery. With the breast cancer indication already approved in the European Union, the strong reception at EUSOBI underscores the continued commercial traction for ProSense® in the region.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.